We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Hikma Pharmaceuticals Plc | LSE:HIK | London | Ordinary Share | GB00B0LCW083 | ORD SHS 10P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -14.00 | -0.65% | 2,132.00 | 96,101 | 12:09:07 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 2,132.00 | 2,134.00 | 2,142.00 | 2,120.00 | 2,136.00 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | USD 3.13B | USD 359M | USD 1.6179 | 13.18 | 4.76B |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 12:04:53 | AT | 250 | 2,132.00 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 10/6/2025 | 11:58 | ALNC |  DIRECTOR DEALINGS: Hikma exec and AB Dynamics advisor sell shares |
| 09/6/2025 | 15:33 | UK RNS | Hikma Pharmaceuticals Plc Director/PDMR Shareholding |
| 06/6/2025 | 13:21 | ALNC | DIRECTOR DEALINGS: Mitie and Wizz Air CEOs buy after share falls |
| 05/6/2025 | 14:05 | UK RNS | Hikma Pharmaceuticals Plc Director/PDMR Shareholding |
| 03/6/2025 | 13:02 | UK RNS | Hikma Pharmaceuticals Plc Director/PDMR Shareholding |
| 29/5/2025 | 10:04 | ALNC | IN BRIEF: Fitch follows S&P in raising Hikma Pharmaceuticals to BBB |
| 29/5/2025 | 07:00 | UK RNS | Hikma Pharmaceuticals Plc Fitch upgrades Hikma to ‘BBB’ |
| 20/5/2025 | 14:49 | UK RNS | Hikma Pharmaceuticals Plc Director/PDMR Shareholding |
| 15/5/2025 | 12:52 | ALNC | Hikma shares climb on new outlook, targets USD5 billion sales by 2030 |
| 15/5/2025 | 12:00 | UK RNS | Hikma Pharmaceuticals Plc Medium-term Group guidance ahead of US site visit |
Hikma Pharmaceuticals (HIK) Share Charts1 Year Hikma Pharmaceuticals Chart |
|
1 Month Hikma Pharmaceuticals Chart |
Intraday Hikma Pharmaceuticals Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 16/5/2025 | 08:26 | Hikma Pharmaceuticals | 1,788 |
| 13/1/2015 | 15:12 | *** Hikma *** | 98 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 11:04:53 | 2,132.00 | 250 | 5,330.00 | AT |
| 11:02:24 | 2,130.98 | 233 | 4,965.19 | O |
| 11:02:09 | 2,132.00 | 188 | 4,008.16 | AT |
| 11:02:09 | 2,132.00 | 75 | 1,599.00 | AT |
| 11:02:09 | 2,132.00 | 16 | 341.12 | AT |
| Top Posts |
|---|
Posted at 13/6/2025 09:20 by Hikma Pharmaceuticals Daily Update Hikma Pharmaceuticals Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker HIK. The last closing price for Hikma Pharmaceuticals was 2,146p.Hikma Pharmaceuticals currently has 221,886,453 shares in issue. The market capitalisation of Hikma Pharmaceuticals is £4,730,619,178. Hikma Pharmaceuticals has a price to earnings ratio (PE ratio) of 13.18. This morning HIK shares opened at 2,136p |
Posted at 07/11/2024 11:55 by martinmc123 4*Hikma issued an encouraging trading update this morning. The Group is performing well and management continue to expect Group revenue to grow in the range of 6% to 8% and for core operating profit to be in the range of $700 million to $730 million in 2024, in line with previously upgraded guidance. All 3 segments - Injectables, Branded and Generics – are performing well...from WealthOracle wealthoracle.co.uk/d |
Posted at 01/11/2024 08:51 by dartboard1 Not so much relevant to HIK tho as they only sell generics in North America I believe, non to EU market. Unless anyone knows otherwise. |
Posted at 10/9/2024 15:08 by hopeful holder I am a little perplexed here.. good performing company, significant improvements over last 12 months, expanding product range, increases in production capability and market potential yet the share price is being stubborn about reflecting that rise.Is this an unloved share or an unloved sector or has the market not picked up on the actual sand potentials here?Any views certainly invited. |
Posted at 23/8/2024 14:57 by hopeful holder Apols for delay...The large uncrossing... appears little volume for a while and uncrossing trace unusually large.200k share is 4 million quid. In the context over previous closes it seemed awfully high and wondered if it indicated larger seller / buys around that may place up or down pressure.Whilst I think the share price should be higher, mr market currently disagrees despite a good recent update. |
Posted at 12/8/2024 19:47 by dartboard1 What's your point, it was at the market price. Only reason to get excited would be if it was materially divergent from it...Not knocking, just interested in what you think it's telling you ... |
Posted at 25/4/2024 13:24 by boadicea Nothing exceptional in the tu - just confirms that it is relatively cheap as Adam notes.Odd initial negative reaction this morning, quickly reversed and those getting in early now have a quick gain. I would think that it should share in a general recovery of the sector if interest rates moderate. |
Posted at 13/1/2024 21:31 by hopeful holder So far, HIK has proven to be better even over this short period. |
Posted at 30/8/2023 08:57 by robertball Not caught by Us drug announcement yesterday re price controls... |
Posted at 02/3/2023 19:01 by ariane Iain GilbertSharecast News 27 Feb, 2023 16:26 27 Feb, 2023 16:27 Broker tips: Hikma Pharmaceuticals Analysts at Berenberg raised their target price on drugmaker Hikma Pharmaceuticals from 1,440.0p to 1,740.0p on Monday on the back of the group's recent trading update. Berenberg stated that last week, Hikma reported "decent" 2022 results, in its view, with no real changes to the group's outlook from January when management presented at a competitor conference. |
Posted at 08/2/2023 13:45 by adamb1978 Share price has had a nice run over the last 3-4 months however is still very cheap if you believe it can grow at mid single digit %s which market forecasts suggest and generate the 20%-ish ROCE which it historically has.If you believe in mean reversion and see it getting back to multiples over the last few years, this should be heading to £25-£30 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
